research

Mesoblast Limited (MESO) Discusses Cellular Medicine Platforms and Innovations at R&D Day Transcript

Seeking Alpha

2 min read

0 likes

⚡ Quantum Brief

Mesoblast’s inaugural R&D Day (April 2026) showcased its cellular medicine platform, led by CEO Silviu Itescu, highlighting advancements in regenerative therapies using allogeneic mesenchymal stem cells (MSCs) for inflammatory and degenerative diseases. Key opinion leaders (KOLs) joined fireside chats, including researchers like Joanne Kurtzberg and Emerson Perin, to discuss clinical progress and potential applications in cardiovascular, neurological, and autoimmune conditions. The event emphasized manufacturing scalability, with Head of Manufacturing Justin Horst detailing proprietary bioreactor technologies to ensure consistent, high-volume MSC production for global commercialization. Chief Medical Officer Eric Rose outlined late-stage trials, including Phase 3 results for chronic heart failure and acute respiratory distress syndrome (ARDS), positioning Mesoblast for near-term regulatory submissions. Commercial strategies were presented by Chief Commercial Officer Marcelo Santoro, focusing on partnerships with pharmaceutical firms to accelerate market adoption and expand therapeutic indications.

AI Audio Summary

0:00 / 0:00

Click to play

Quantum News · Media Library

Understand this faster with AI

Ask ChatGPT

Research with Perplexity

Explain with Claude

Discuss on Grok

SA Transcripts159.25K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Mesoblast Limited (MESO) Discusses Cellular Medicine Platforms and Innovations at R&D Day April 8, 2026 8:00 AM EDT Company Participants Paul Hughes - Global Head of Corporate Communications & Joint Company SecretarySilviu Itescu - Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director Marcelo Santoro - Chief Commercial OfficerMichael Schuster - Co-Founder and Head of Pharma PartneringRoger BrownKenneth Borow - ExecutiveEric Rose - Chief Medical Officer & Executive DirectorDaniel DevineJustin Horst - Head of ManufacturingJames O’Brien - Chief Financial OfficerMichael Schuster Conference Call Participants Joanne KurtzbergSusan ProckopDouglas BeallEmerson PerinSaad J. KenderianThaddeus Barney - Piper Sandler & Co., Research DivisionThomas Shrader - BTIG, LLC, Research DivisionDouglas P. BeallMichael Okunewitch - Maxim Group LLC, Research DivisionEdward Tenthoff - Piper Sandler & Co., Research Division Conversation Paul HughesGlobal Head of Corporate Communications & Joint Company Secretary Good morning, and welcome, everyone, to Mesoblast's inaugural R&D Day. We've got a wonderful morning planned and appreciate you all investing the time to come along and hear the Mesoblast story. Before we get started, I'll just draw your attention to the slide, the forward-looking statement that I've got displayed on the screen. Okay. So the format will be presentations from Mesoblast program heads and our leaders. And they will be followed by a fireside chat with KOLs, and then we'll conclude with Q&A. We're delighted to have such a distinguished lineup of industry key opinion leaders for you to hear from today, and we're very grateful for their time. And with that, I'll now hand over to Silviu, Mesoblast's Chief Executive. Silviu ItescuFounder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director Good morning, everybody, and thank you for coming. We're very excited to have our inaugural R&D Day and it's great to have so many friends in the audience. So nice to see

Read Original

Source Information

Source: Seeking Alpha

Website: https://seekingalpha.com/feed.xml

Discussion

0 professional contributions

Be the first to add a constructive contribution.